Spexis AG
SPEX | SW
Overview
Corporate Details
- ISIN(s):
- CH0106213793
- LEI:
- 391200S8HJE1I96FIG04
- Country:
- Switzerland
- Address:
- Hegenheimermattweg 125, 4123 Allschwil
- Website:
- https://www.polyphor.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Headquartered in Switzerland and Boston, two global biotech-hubs, our ambition is to develop Spexis into a leading biopharmaceutical company with a strategic focus on rare diseases, oncology and antimicrobial resistance. With a strong scientific core, our drug discovery and research efforts are led by our in house scientist via leveraging our discovery platforms in collaboration with top academic centers around the globe. We have two clinical programs focused on products for rare, chronic respiratory diseases. Spexis AG is a combination of the two legacy companies, Polyphor, a publicly listed Swiss biotech and EnBiotix, a privately held US biotech. In December 2021, two companies – Polyphor and EnBiotix – teamed up to join forces and formed Spexis.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2024-11-05 07:15 |
Delisting Announcement
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
|
English | 9.3 KB | |
| 2024-11-05 01:00 |
Delisting Announcement
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
|
English | 7.7 KB | |
| 2024-07-29 07:15 |
Legal Proceedings Report
Spexis granted definitive moratorium status until 25 November 2024, subject to …
|
English | 8.6 KB | |
| 2024-07-29 02:00 |
Legal Proceedings Report
Spexis granted definitive moratorium status until 25 November 2024, subject to …
|
English | 6.9 KB | |
| 2024-07-22 07:15 |
Legal Proceedings Report
Spexis expects that audit of its 2023 financials will not be completed by 31 Ju…
|
English | 10.8 KB | |
| 2024-07-22 02:00 |
Legal Proceedings Report
Spexis expects that audit of its 2023 financials will not be completed by 31 Ju…
|
English | 9.1 KB | |
| 2024-07-08 07:15 |
Legal Proceedings Report
Spexis AG: PARI Pharma GmbH announces termination of ColiFin license to EnBioti…
|
English | 10.0 KB | |
| 2024-07-08 02:00 |
Legal Proceedings Report
Spexis AG: PARI Pharma GmbH announces termination of ColiFin® license to EnBiot…
|
English | 8.4 KB | |
| 2024-06-04 20:00 |
Delisting Announcement
Spexis launches appeal against SIX Exchange Regulation decision to suspend trad…
|
English | 8.0 KB | |
| 2024-06-04 02:00 |
Delisting Announcement
Spexis launches appeal against SIX Exchange Regulation decision to suspend trad…
|
English | 6.4 KB | |
| 2024-05-31 22:00 |
Report Publication Announcement
Spexis receives second extension for the publication of its 2023 annual report …
|
English | 19.4 KB | |
| 2024-05-31 02:00 |
Report Publication Announcement
Spexis receives second extension for the publication of its 2023 annual report …
|
English | 16.6 KB | |
| 2024-04-30 20:30 |
Report Publication Announcement
Spexis receives approval of an extension of the deadline for the publication of…
|
English | 9.8 KB | |
| 2024-04-30 02:00 |
Report Publication Announcement
Spexis receives approval of an extension of the deadline for the publication of…
|
English | 8.2 KB | |
| 2024-04-17 07:15 |
Regulatory News Service
Spexis announces extension of moratorium, receipt of an additional payment rela…
|
English | 13.8 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-21 | N/A | Executive member | Other | None | N/A |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |